Abiomed has enrolled the first patient in the PROTECT IV trial, which aims to obtain the clinical evidence needed to get a Class I guideline recommendation for Impella heart pumps in high-risk percutaneous coronary intervention (HRPCI).
The first patient was enrolled at Ascension St John Hospital in Detroit, US.
Ascension St John Macomb-Oakland Hospital cardiology chief Dr Ted Schreiber said: “This trial aims to generate the highest level of scientific clinical evidence to definitively demonstrate that Impella-supported PCI improves outcomes for high-risk patients, and we are excited to enrol the first patient in the trial.”
